Scarica l'app Stockscreener
2.19
3.30%
0.07
Precedente Chiudi:
$2.12
Aprire:
$2.145
Volume 24 ore:
17,282
Relative Volume:
1.05
Capitalizzazione di mercato:
$14.83M
Reddito:
-
Utile/perdita netta:
$-33.65M
Rapporto P/E:
-0.4398
EPS:
-4.98
Flusso di cassa netto:
$-20.83M
1 W Prestazione:
-5.60%
1M Prestazione:
-13.95%
6M Prestazione:
-10.98%
1 anno Prestazione:
-56.20%
Intervallo 1D:
$2.14
$2.2299
Intervallo di 1 settimana:
$2.0703
$2.345
Portata 52W:
$2.0703
$13.49
Minerva Neurosciences Inc Stock (NERV) Company Profile
Nome
Minerva Neurosciences Inc
Settore
Industria
Telefono
617-600-7373
Indirizzo
1601 TRAPELO ROAD, WALTHAM, MA
Confronta NERV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| NERV | 2.21 | 14.83M | 0 | -33.65M | -20.83M | -4.98 |
| VRTX | 449.62 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.76 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 598.25 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.24 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.28 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-06-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Iniziato | BTIG Research | Buy |
| 2019-10-02 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-25 | Iniziato | Chardan Capital Markets | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-31 | Iniziato | H.C. Wainwright | Buy |
| 2017-09-01 | Iniziato | Citigroup | Buy |
| 2017-03-06 | Ripresa | Jefferies | Buy |
| 2016-05-12 | Ripresa | Jefferies | Buy |
Mostra tutto
Minerva Neurosciences Inc Borsa (NERV) Ultime notizie
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
500: Something went wrong - Investing.com
Minerva Neurosciences stock hits 52-week low at $2.25 By Investing.com - Investing.com Canada
Minerva Neurosciences’ (NERV) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges - TipRanks
Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Cognitive Impairment Disorders Treatment A Game Changer for Global Finance Forecast-Eli Lilly and Company, AstraZeneca, – IndiaPolitics.com - IndiaPolitics.com
Japan Receptor Tyrosine Protein Kinase ERBB 4 Industry Size, Share, Price, Trends, Forecast (2024-2034) - IndiaPolitics.com
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Inari Medical director sells $1.83M in common stock - TipRanks
Intuitive Machines Shares Soar on NASA Pact for Near-Space Grid - Bloomberg
Intuitive Machines Stock Soars on New NASA Contract. This Is Big. - Barron's
Intuitive Machines Stock Is Soaring Wednesday: What's Going On? - Benzinga
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com Australia
Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com - Defense World
Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
INmune Bio stock dips on $13M securities offering - MSN
Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Rubertis Francesco De Net Worth (2024) - GuruFocus.com
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Research Analysts Issue Forecasts for Minerva Neurosciences, Inc.’s Q3 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Price Target Cut to $5.00 - Defense World
HC Wainwright Weighs in on Minerva Neurosciences, Inc.’s Q4 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences: Q2 Earnings Snapshot - San Antonio Express-News
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average of $4.42 - Defense World
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Cognitive Behavioral Therapy for Insomnia Market Insights, Industry Outlook, Growing Trends with Top Key Players – MINERVA NEUROSCIENCES INC, CURRAX PHARMACEUTICALS LLC, Pfizer Inc., Sanofi, zydus cadila – TIMC - TIMC
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Below 200-Day Moving Average of $4.54 - Defense World
Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research
Are Options Traders Betting on a Big Move in Minerva Neurosciences (NERV) Stock? - Yahoo Lifestyle UK
Design, Sarepta, Wave rise amid overall neurological index decline - BioWorld Online
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates - Quantisnow
Minerva Neurosciences Announces Listing Transfer to Nasdaq Capital Market - Quantisnow
Minerva Neurosciences Reports Second Quarter 2021 Financial Results and Business Updates - Quantisnow
Minerva Neurosciences to Report Fiscal Year 2022 Financial Results and Business Updates on March 8, 2023 - Quantisnow
Minerva Neurosciences to Present at JMP Securities Life Sciences Conference - Quantisnow
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million - Quantisnow
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates - Quantisnow
Minerva Neurosciences to Report Second Quarter 2021 Financial Results and Business Updates on August 2, 2021 - Quantisnow
Minerva Neurosciences to Report Third Quarter 2021 Financial Results and Business Updates on November 8 - Quantisnow
Minerva Neurosciences Inc Azioni (NERV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.80%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):